https://www.bioworld.com/rss en-us Breezebio Inc. (formerly Genedit Inc.) has entered into a joint research agreement with Ligachem Biosciences Inc. to develop innovative cancer vaccine therapies. http://www.bioworld.com/articles/732806 Tue, 21 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732806-breezebio-and-ligachem-partner-on-cancer-vaccine-research Vaccine vial and syringe U.S. Health and Human Services Secretary Robert Kennedy was the 800-pound gorilla that couldn’t be ignored as the Senate Health, Education, Labor and Pensions Committee held a joint confirmation hearing July 15 for President Donald Trump’s nominees for CDC director and the head of the Administration for Strategic Preparedness and Response. http://www.bioworld.com/articles/732609 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732609-cdc-nominees-qualifications-shadowed-by-kennedy-agenda Erica Schwartz, CDC director nominee Erica Schwartz, nominee for CDC director, speaks at the Senate Health, Education, Labor and Pensions Committee joint confirmation hearing held July 15. Credit: help.senate.gov The Oxford Vaccine Group has delivered on its promise, and after starting work in mid-May has completed preclinical testing and is ready to begin a phase I trial of a vaccine against the Bundibugyo Ebola virus that is causing the current serious disease outbreak in the Democratic Republic of Congo. http://www.bioworld.com/articles/732596 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732596-first-purpose-designed-ebola-bundibugyo-vaccine-ready-for-phase-i Close-up of a medical syringe Human cytomegalovirus (CMV) is a clinical challenge in infants and immunocompromised individuals, since no licensed vaccine exists. Vaccine development is complex due to several factors, including viral latency, genomic complexity and immune evasion, among others. Evaxion A/S recently presented data on its proprietary AI-immunology platform used to create the EVX-V1 vaccine for CMV infection. http://www.bioworld.com/articles/732627 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732627-preclinical-data-support-evaxions-platform-behind-cmv-vaccine-candidate Cytomegalovirus in a human cell What appears to be a routine item on a routine list of the U.S. Department of Health and Human Services’ (HHS) proposed rulemakings for the next fiscal year is being seen as anything but routine, given HHS Secretary Robert Kennedy’s stance on vaccines and several commonly used drugs. http://www.bioworld.com/articles/732516 Thu, 09 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732516-covid-19-injuries-posting-of-crls-on-hhs-2027-rulemaking-agenda US flag and HHS logo Credit: mehaniq41 Abera Bioscience AB has completed a ferret study with its intranasal influenza vaccine candidate. The results were consistently strong and encourage the continued development of the program. Abera intends to publish detailed study data in a peer-reviewed scientific journal. http://www.bioworld.com/articles/732360 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732360-aberas-intranasal-influenza-vaccine-shows-promise-in-ferrets Nasal spray For the second time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled a scheduled meeting due to a federal judge’s stay that keeps the panel from meeting with its current membership. Typically, ACIP meets three times a year – in February, June and October. The 2026 June meeting was slated for June 23-25. Whether the adcom meets in October will be up to the courts and how far Health and Human Services Secretary Robert Kennedy digs in his heels to maintain a hand-picked committee tilted toward his view of vaccines. http://www.bioworld.com/articles/732159 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732159-uncertainty-reigns-as-acip-remains-on-court-hold Empty meeting room When it comes to vaccines and preparedness, platform delivery technologies can be both a boon and a barrier. On the one hand, an existing platform can speed development of a vaccine targeting an unexpected viral scare such as the recent Bundibugyo Ebola and Andes hantavirus outbreaks. On the other hand, the intellectual property (IP) protecting that platform adds to the economic hurdles facing smaller vaccine developers, Douglas Bucklin, a life sciences patent attorney with Volpe Koenig, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/732079 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732079-platform-technology-ip-adds-to-vaccine-challenge Virtual IP display Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is channeling cash flow from these blockbuster GLP-1 drugs into an aggressive dealmaking campaign — about $25.1 billion across 10 announced acquisitions so far this year and more than $26 billion in other closed deals. http://www.bioworld.com/articles/732076 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732076-lillys-glp-1-windfall-fuels-m-and-a-land-grab-across-10-deals-25b Business handshake and holographic dollar sign Replicate Bioscience Inc. has been awarded a new grant worth approximately $3 million from the Gates Foundation to accelerate the development of globally accessible tuberculosis (TB) vaccines using Replicate’s clinically validated self-replicating RNA (srRNA) platform. http://www.bioworld.com/articles/732093 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732093-grant-supports-replicates-srrna-vaccine-development-for-tb Mycobacterium tuberculosis Mycobacterium tuberculosis. Credit: NIAID The Andes virus, a member of the Hantaviridae, is the only member of this family known to have the ability to spread efficiently from person to person through close contact with respiratory secretions. In a letter published in The Lancet, researchers from the University of Texas Medical Branch report they demonstrated the potential of single-dose mRNA vaccines against Andes hantavirus. The Lancet, researchers from the University of Texas Medical Branch report they demonstrated the potential of single-dose mRNA vaccines against Andes hantavirus.]]> http://www.bioworld.com/articles/732091 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732091-study-of-single-dose-mrna-vaccines-against-andes-hantavirus-in-hamsters Evaxion A/S has developed EVX-04, an AI-designed DNA vaccine encoding 1β endogenous retroviruses (ERVs)-derived antigenic fragments to induce broad antigen-specific T-cell responses targeting acute myeloid leukemia blasts expressing ERV antigens. http://www.bioworld.com/articles/732031 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732031-evaxion-shares-data-from-characterization-of-evx-04 The U.S. FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of Moderna Inc.’s trivalent mRNA flu vaccine, mRNA-1010, which the company wants to brand as Mflusiva. On the question of whether the benefits of the product outweigh the risks in people ages 50 to 64, balloting was 9-0, and on whether the same is true in those 65 and older, the tally was again 9-0. http://www.bioworld.com/articles/731917 Thu, 18 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731917-table-turned-modernas-high-fi-flu-shot-plays-well-at-adcom Elderly person receiving shot Abera Bioscience AB has announced the decision by CEPI (Coalition for Epidemic Preparedness Innovations) to extend the ongoing project supporting the development of Abera’s BERA vaccine platform and the company’s influenza vaccine candidate. The project period has been extended until Dec. 31, 2026, with the budget unchanged. http://www.bioworld.com/articles/732009 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732009-cepi-extends-support-for-aberas-vaccine-platform Vial and syringe with blue hues On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers at Washington University School of Medicine in St. Louis have reported that the vaccine conferred broader and more durable protection than a standard flu shot. http://www.bioworld.com/articles/731989 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731989-mrna-flu-vaccine-can-activate-broad-germinal-center-response mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles Moderna Inc. will soon find out if the tumult-ridden U.S. FDA’s switcheroo in mid-February will stick regarding mRNA-1010, a prospective new seasonal influenza vaccine. The Vaccines and Related Biological Products Advisory Committee on June 17 takes up the matter of the shot, which trails a curious history. http://www.bioworld.com/articles/731890 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731890-another-shot-moderna-flu-vaccine-re-upped-in-adcom Syringe in front of Moderna logo Credit: Asiraj - stock.adobe.com Backers of Boston-based Elicio Therapeutics Inc. may have jumped the gun as they ran away from the firm after data were made public from the phase II Amplify-7P study testing ELI-002 7P in adjuvant KRAS-mutation-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional therapy. Wainwright analyst Robert Burns said the results are “more nuanced than they appear” and the sell-off represents “an attractive entry point” for investors. Shares (NASDAQ:ELTX) closed June 15 at $4.08, down $10.77, or 72%, in the wake of news that the trial missed the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population. http://www.bioworld.com/articles/731873 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731873-do-phase-ii-data-amplify-kras-pdac-promise-for-elicio Dollar sign, downward arrow The University of Oxford and Moderna Inc. have announced authorization by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of mRNA-4194, Moderna’s investigational mRNA-based cancer vaccine for Lynch syndrome. http://www.bioworld.com/articles/731760 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731760-modernas-mrna-4194-cleared-for-clinic-for-lynch-syndrome Illustration of messenger RNA The Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $9.7 million in additional funding to Pop Biotechnologies Inc. to advance the company’s Pop Bio SNAP (Spontaneous Nanoliposome Antigen Particle) protein vaccine platform into a phase I trial. http://www.bioworld.com/articles/731654 Thu, 04 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731654-cepi-backs-pop-biotechnologies-nanoparticle-vaccine-platform Nanoparticle illustration Nearly a year after Health and Human Services Secretary Robert Kennedy announced the U.S. was cutting off funding for Gavi, a global vaccine alliance, Secretary of State Marco Rubio said his department is reengaging with the organization in light of the ongoing Ebola outbreak in central Africa. In testifying before a June 2 Senate Foreign Relations Committee hearing, Rubio said the State Department made the decision to reengage a few weeks earlier with Gavi. He provided no detail of what that engagement looks like. http://www.bioworld.com/articles/731543 Wed, 03 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731543-rubio-reopening-door-with-gavi Smartphone with webpage of Gavi, The Vaccine Alliance Credit: Timon - stock.adobe.com The Coalition for Epidemic Preparedness Innovations (CEPI) has announced funding and support to urgently accelerate development of three investigational vaccines targeting the Bundibugyo Ebola virus. http://www.bioworld.com/articles/731577 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731577-cepi-backs-vaccine-candidates-for-bundibugyo-ebola-virus Dollar sign inside vial, syringe Moderna Inc. has announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo Ebola virus (BDBV), a cause of Ebola virus disease. http://www.bioworld.com/articles/731557 Mon, 01 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731557-cepi-supports-modernas-vaccine-against-bundibugyo-ebola-virus Gloved hands holding mRNA vaccine vial Landing on the right COVID-19 vaccine formulation for the coming season is becoming more complicated against a backdrop of low vaccination rates, young children with little to no immunization, declining surveillance data and a new SARS-COV-2 lineage slowly emerging. http://www.bioworld.com/articles/731442 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731442-fdas-vrbpac-faces-complex-covid-19-landscape COVID-19 vaccine vials on conveyor belt Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway in the U.S. and U.K., and the Serum Institute of India is standing ready to manufacture the vaccine for clinical trials. If the animal tests are positive, the vaccine will be ready for clinical trials in two to three months. http://www.bioworld.com/articles/731490 Wed, 27 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731490-work-underway-on-vaccines-antivirals-against-rare-bundibugyo-ebola-outbreak Ebola virus in petri dish with lab, scientist background Eli Lilly and Co. has offered to buy three vaccine companies for up to $3.8 billion combined, including up to $1.55 billion for Vaccine Company Inc., whose in vivo nanoparticle (IVN) technologies are designed to enable antigens that elicit durable immune responses, much like virus-like particle (VLP) vaccines, but avoid the VLP manufacturing burden. http://www.bioworld.com/articles/731290 Wed, 27 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731290-eli-lilly-offers-to-buy-three-vaccine-makers What would normally be a routine meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee May 28 may be more carefully watched given the overall turmoil surrounding vaccines in the U.S. The only task before the adcom is to recommend the COVID-19 vaccine formula for the upcoming season. That conversation will include looking at the effectiveness of the four FDA-approved vaccines currently in use in the U.S. http://www.bioworld.com/articles/731405 Tue, 26 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731405-fda-adcom-to-consider-next-iteration-of-covid-19-vaccines Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway in the U.S. and U.K., and the Serum Institute of India is standing ready to manufacture the vaccine for clinical trials. If the animal tests are positive, the vaccine will be ready for clinical trials in two to three months. http://www.bioworld.com/articles/731403 Tue, 26 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731403-work-underway-on-vaccines-antivirals-against-rare-bundibugyo-ebola-outbreak Ebola virus in petri dish with lab, scientist background As the most active biopharma acquirer of 2026, Eli Lilly and Co. offered to buy three vaccine companies for up to $3.8 billion combined, while it simultaneously released positive early clinical results of a gene editing medicine brought into the fold last year through its buyout of Verve Therapeutics Inc. http://www.bioworld.com/articles/731401 Tue, 26 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731401-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise Syringes in virus cell; Lilly, Curevo, Limmatech, Vaccine Company logos Although influenza virus infection can be particularly life-threatening among young infants, approved vaccines are lacking for infants under 6 months. Aiming to overcome the required annual updates to the influenza vaccine, recent efforts have focused on generating vaccines that promote broadly reactive antibodies (Abs) targeting conserved regions of viral proteins, such as the stem domain of hemagglutinin (HA). http://www.bioworld.com/articles/731273 Tue, 26 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731273-dual-adjuvant-ha-stem-nanoparticle-vaccine-generates-protective-immune-response 3D illustration showing surface glycoprotein spikes hemagglutinin (purple) and neuraminidase (orange) The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of the virus, for which there are no approved vaccines or antiviral therapies. At the same time, the high positivity rate, with eight laboratory confirmed cases out of 13 samples collected in various areas, and more reports of suspected cases and clusters of deaths, all point to a potentially much larger outbreak than currently is being detected and reported. http://www.bioworld.com/articles/731367 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731367-who-declares-ebola-outbreak-a-public-health-emergency-of-international-concern Microscopic view of the ebola virus